Elanco Animal Health Incorporated (NYSE:ELAN) reported fourth-quarter revenue of $1.02 billion, a decrease of 1% on a ...

Full Year 2024 Results Key Financial Results Revenue: US$4.44b (flat on FY ...

Private Advisor Group LLC increased its position in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 6.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The ...

Morgan Stanley lowered the firm’s price target on Elanco (ELAN) to $13 from $14 and keeps an Equal Weight rating on the shares. Q4 EPS of 14c ...

Stifel analyst Jonathan Block lowered the firm’s price target on Elanco (ELAN) to $15 from $16 and keeps a Buy rating on the shares. While the ...

Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...

Elanco Animal Health will commercialize an avian flu vaccine for dairy cattle after reaching an agreement with Medgene.

Elanco Animal Health inks agreement with Medgene to commercialize highly pathogenic avian influenza vaccine in dairy cattle: Greenfield, Indiana Wednesday, February 26, 2025, 15:0 ...

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.

Elanco Animal Health narrowed its fourth-quarter loss despite lower sales, but its forecast for the current quarter and full year came in below Wall Street's estimates.

Revenue of $1,020 million, decreased 1% on a reported basis and increased 4% on an organic constant currency basis Reported ...